MA50341A - Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique - Google Patents

Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique

Info

Publication number
MA50341A
MA50341A MA050341A MA50341A MA50341A MA 50341 A MA50341 A MA 50341A MA 050341 A MA050341 A MA 050341A MA 50341 A MA50341 A MA 50341A MA 50341 A MA50341 A MA 50341A
Authority
MA
Morocco
Prior art keywords
prednisone
administration
treatment
methods
prostate cancer
Prior art date
Application number
MA050341A
Other languages
English (en)
Inventor
Namphuong Tran
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of MA50341A publication Critical patent/MA50341A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050341A 2017-10-11 2018-02-08 Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique MA50341A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762570781P 2017-10-11 2017-10-11

Publications (1)

Publication Number Publication Date
MA50341A true MA50341A (fr) 2020-08-19

Family

ID=61283312

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050341A MA50341A (fr) 2017-10-11 2018-02-08 Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique

Country Status (16)

Country Link
US (2) US20190105332A1 (fr)
EP (1) EP3694604A1 (fr)
JP (1) JP2020536903A (fr)
KR (1) KR20200068689A (fr)
CN (1) CN111542373A (fr)
AU (1) AU2018347804A1 (fr)
BR (1) BR112020007090A2 (fr)
CA (1) CA3077678A1 (fr)
EA (1) EA202090916A1 (fr)
IL (1) IL273826A (fr)
JO (1) JOP20200072A1 (fr)
MA (1) MA50341A (fr)
MX (1) MX2020003830A (fr)
PH (1) PH12020550151A1 (fr)
UA (1) UA124865C2 (fr)
WO (1) WO2019074536A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240115925A (ko) 2016-07-29 2024-07-26 얀센 파마슈티카 엔브이 전립선암의 치료 방법
BR112022021732A2 (pt) * 2020-05-08 2022-12-06 Janssen Pharmaceutica Nv Tratamentos de câncer de próstata com combinações de acetato de abiraterona e niraparibe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898495B (zh) * 2012-11-12 2014-11-26 浙江神洲药业有限公司 醋酸阿比特龙酯的制备方法

Also Published As

Publication number Publication date
PH12020550151A1 (en) 2021-02-08
MX2020003830A (es) 2020-11-06
JOP20200072A1 (ar) 2020-04-29
EP3694604A1 (fr) 2020-08-19
CN111542373A (zh) 2020-08-14
BR112020007090A2 (pt) 2020-09-24
KR20200068689A (ko) 2020-06-15
WO2019074536A1 (fr) 2019-04-18
US20200069704A1 (en) 2020-03-05
AU2018347804A1 (en) 2020-04-16
EA202090916A1 (ru) 2020-12-11
US20190105332A1 (en) 2019-04-11
IL273826A (en) 2020-05-31
CA3077678A1 (fr) 2019-04-18
JP2020536903A (ja) 2020-12-17
UA124865C2 (uk) 2021-12-01

Similar Documents

Publication Publication Date Title
IL280707A (en) Diagnostic and therapeutic methods for treating breast cancer
HRP20210200T1 (hr) Kombinirana antitumorska imunoterapija
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
JO3606B1 (ar) معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا
EA201992430A1 (ru) Комбинированная терапия рака предстательной железы
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
CY1124554T1 (el) Μεθοδοι και συνθεσεις για διεγερση του εντερικου εντεροενδοκρινους συστηματος για θεραπεια ασθενειων ή καταστασεων που σχετιζονται προς αυτο
BR112017000703A2 (pt) métodos para tratar ou retardar a progressão do câncer, para reduzir ou inibir a reincidência do câncer, para tratar ou retardar a progressão da imunidade tumoral e para aumentar, intensificar ou estimular uma resposta ou função imune e kit
MA56212A (fr) Compositions et méthodes de traitement du cancer
MX2021013965A (es) Composiciones anticancerigenas.
IL258854A (en) Preparations containing cannabidiol and secondary medicinal agents for cancer treatment
MA46361A (fr) Traitement du cancer de la prostate
MA47172A (fr) Compositions et procédés de traitement des inflammations intestinales et du cancer du côlon
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MA47436A (fr) Traitement de la mucopolysaccharidose i avec une alpha-l-iduronidase glycosylée entièrement humaine (idua)
MA50341A (fr) Méthodes de traitement du cancer de la prostate par administration d'acétate d'abiratérone et de prednisone avec une thérapie par privation androgénique
IL257670A (en) Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer
MA55717A (fr) Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
IL304245A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment
EA201892631A1 (ru) Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака
IL265675A (en) Methods for diagnosis and treatment of prostate cancer resistant to abiraterone acetate-glucocorticoid or sensitive to metastatic castration
MX2017011237A (es) Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP3817774A4 (fr) Compositions et méthodes pour l'administration locale d'agents pharmaceutiques pour traiter le cancer